NeoGenomics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEO research report →
Range $19 – $28
Price Chart
About the company
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services.
- CEO
- Anthony Zook
- IPO
- 2004
- Employees
- 2,500
- HQ
- Fort Myers, FL, US
Get TickerSpark's AI analysis on NEO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.93B
- P/E
- -63.72
- Fwd P/E
- 72.65
- PEG
- -0.49
- P/S
- 0.52
- P/B
- 2.53
- EV/EBITDA
- 22.29
- Div Yield
- 0.00%
- Gross Margin
- 43.80%
- Op Margin
- -5.98%
- Net Margin
- -4.10%
- ROE
- -3.97%
- ROIC
- -3.32%
Latest fiscal year · YoY change
- Revenue
- $727.33M+10.1%
- Gross Profit
- $282.54M-2.6%
- Op Income
- $-66,078,999
- Net Income
- $-108,025,000-37.2%
- EPS
- $-0.84-35.5%
- OCF Growth
- -25.5%
- FCF Growth
- +36.0%
- 52W High
- $20.15
- 52W Low
- $7.07
- 50D MA
- $17.32
- 200D MA
- $13.07
- Beta
- 1.83
- RSI (14)
- 34
- Avg Volume
- 1.96M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NeoGenomics delivered an above-expectations third quarter with strong NGS momentum, margin expansion, and raised full-year revenue and EBITDA guidance, while also outlining a CEO transition to Warren Stone.· October 28, 2026
- Total revenue was $209 million, up 11% year over year, with clinical revenue up 13% to $195 million.
- NGS revenue rose 29% year over year on 17% volume growth and above-25% growth in large-panel volumes.
- Adjusted gross margin expanded by over 300 basis points to 49%, and adjusted EBITDA increased 53% year over year to $18.7 million.
- Management raised 2026 guidance to revenue of $807 million to $809 million and adjusted EBITDA of approximately $60 million.
- RaDaR ST reimbursement progress, an expanded sales force, and Lab of the Future investments remain key growth drivers, while nonclinical revenue remained a modest drag.
Third quarter revenue was $209 million, up 11% year over year. Clinical revenue grew 13% to $195 million, driven by a 2% increase in test volumes and an 11% increase in AUP. NGS revenue increased 29% year over year, supported by 17% volume growth and above-25% growth in large-panel NGS volumes. Nonclinical revenue was $15 million, down about 10% year over year. Adjusted gross margin was 49%, up more than 300 basis points, adjusted gross profit rose $16 million to $102 million, and adjusted EBITDA was $18.7 million, up 53% year over year. Cash and cash equivalents ended at $139 million, down $6 million from the prior quarter. For 2026, management raised revenue guidance to $807 million to $809 million, from $802 million to $806 million, implying about 11% growth at the midpoint, and raised adjusted EBITDA guidance to approximately $60 million from $56 million to $58 million. Full-year adjusted gross margin improvement is now expected to be well over 150 basis points, with fourth-quarter gross margin expected around 48%.
Tony Zook said the company is seeing stronger momentum across the clinical business, especially NGS, and framed the quarter as evidence that the strategy is working. He emphasized that the leadership transition is happening from a position of strength, with Warren Stone becoming CEO on January 4, 2027, while Tony moves to Executive Chair. Strategically, he highlighted a shift toward higher-value advanced testing modalities, with NGS and MRD expected to become a much larger share of revenue over time.
Abhishek Jain focused on the reported financial performance and the mechanics behind the margin improvement. He cited $209 million of revenue, $195 million of clinical revenue, $102 million of adjusted gross profit, a 49% adjusted gross margin, and $18.7 million of adjusted EBITDA, along with cash of $139 million at quarter-end. He also noted more than $5 million of capex tied to sequencers and data servers for the NovaSeq X transition, roughly $10 million paid for the DOJ settlement reserve, and that the XiFin RCM rollout temporarily affected receivables but should normalize into Q4 and early 2027. On guidance, he raised full-year revenue to $807 million-$809 million and adjusted EBITDA to approximately $60 million.
Analysts pressed on why the CEO transition was happening now, and Tony said it was the result of succession planning and Warren having earned the role through broad operational responsibility and performance. Warren said he has been heavily involved in strategy and people decisions for years and plans to keep the strategy intact while communicating a broader ambition at an Investor Day in the first half of 2027. Questions also focused on NGS growth drivers, with management saying the growth reflects a mix of product launches, field force expansion, customer experience improvements, and a portfolio mindset rather than one single factor. On RaDaR ST, management said about 30% of orders attach to other NeoGenomics tests, volumes are improving month over month, and two additional MolDX indications are under review, while commercial payer wins are increasingly supporting PanTracer Liquid and RaDaR ST.
The bull case from this call is that NeoGenomics is showing durable top-line momentum in its highest-value business lines, with NGS revenue up 29% and large-panel volumes growing above 25%. Management also sounded confident that RaDaR ST reimbursement and broader commercial coverage could become meaningful contributors over time, while the portfolio can drive cross-sell and attach across diagnosis, therapy selection, and MRD monitoring. Margin gains, raised guidance, and continued operating discipline suggest the company believes it can grow while improving profitability.
The main risks discussed were that nonclinical revenue remains a drag, down about 10% year over year, and management is still evaluating low-margin pharma contracts. Management also said the XiFin rollout temporarily affected receivables, and some MRD testing is being run before reimbursement is secured, which Warren said can be a gross margin headwind in the near term. In addition, the company acknowledged that the benefits from NovaSeq X and some RaDaR ST reimbursement expansions are still ahead, so part of the growth story depends on future execution and payer progress.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.1%
- Shares Outstanding
- 129.39M
- Float Shares
- 117.92M
of shares held by institutions
278 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NEO, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 20.09M | ▼ 776.50K |
| Vanguard Group Inc | 13.83M | ▼ 75.38K |
| First Light Asset Management, LLC | 12.28M | ▲ 2.55M |
| Greenhouse Funds Lllp | 8.57M | ▼ 525.89K |
| Vanguard Portfolio Management LLC | 7.79M | ▼ 272.40K |
| First Trust Advisors LP | 7.42M | ▼ 2.69M |
| Vanguard Capital Management LLC | 5.74M | ▼ 18.95K |
| State Street Corp | 5.35M | ▼ 16.95K |
| Nomura Asset Management International Inc. | 5.04M | ▲ 1.59M |
| Braidwell LP | 4.92M | ▼ 699.20K |
| Schroder Investment Management Group | 4.34M | ▲ 774.30K |
| Geode Capital Management, LLC | 3.42M | ▼ 11.68K |
Held by 333 ETFs
Biggest fund positions in NEO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Stone Warren | other | 17,562 |
| Oct 1, 26 | Stone Warren | other | 6,911 |
| Oct 1, 26 | Stone Warren | other | 17,562 |
| Sep 1, 26 | Olivo Alicia C | other | 2,692 |
| Aug 21, 26 | Stone Warren | other | 28,106 |
| Aug 21, 26 | Stone Warren | other | 11,060 |
| Aug 21, 26 | Stone Warren | other | 28,106 |
| Aug 4, 26 | Aunan Greg D | sell | 20,000 |
| Jun 23, 26 | Starrett Carolyn S | other | 14,125 |
| Jun 23, 26 | Starrett Carolyn S | other | 9,784 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NEO coverage
Recent articles, reports, and earnings notes.

Inside the Apex Critical Metals Corp. IPO: Setup, Risks, and Verdict
Apex Critical Metals Corp. American Depositary Shares (NASDAQ: APXC) is expected to list on 2026-10-23, but the price range has not been disclosed. The company is a pre-revenue rare earths and niobium explorer, so the setup hinges on drill progress, funding, and how investors price critical-minerals optionality. Bull case: U.S.-linked critical minerals exposure; bear case: no revenue, no disclosed pricing, and heavy exploration risk.

Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float
Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.
Want a deeper read on NEO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
NeoGenomics Touts 29% Sequencing Growth, Plans Sales Push for Cancer Tests
marketbeat.com · Nov 21
Better Adds Two Mortgage Advisors With $50 Million in Combined Annual Volume Through NEO Home Loans Channel
businesswire.com · Nov 20
NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23
globenewswire.com · Nov 19
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
globenewswire.com · Nov 17
Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel
businesswire.com · Nov 13
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
globenewswire.com · Nov 11
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
globenewswire.com · Nov 11
Neo Performance Materials Q3 Earnings Call Highlights
defenseworld.net · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.